NFKB1 and diffuse large B-cell lymphoma: A20, a negative regulator of NF-κB signaling, is one of the most commonly mutated NF-κB pathway genes in ABC DLBCL, which may also be a biomarker of innate resistance to therapies that target the NF-κB pathway upstream [45].